Lineage Cell Therapeutics, Inc. (LCTX) Total liabilities 2016–2025
Lineage Cell Therapeutics, Inc. (LCTX) total liabilities at each fiscal year-end, per SEC filings.
$69.2MFY2025 · since FY2016: $12.1M → $69.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $69.2M | +91.2% |
| FY2024 | $36.2M | -7.2% |
| FY2023 | $39.0M | -24.6% |
| FY2022 | $51.7M | -38.2% |
| FY2021 | $83.6M | +552.4% |
| FY2020 | $12.8M | -9.9% |
| FY2019 | $14.2M | +51.2% |
| FY2018 | $9.4M | +4.9% |
| FY2017 | $9.0M | -25.6% |
| FY2016 | $12.1M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More LCTX financial trends
LCTX RevenueLCTX Net incomeLCTX Net marginLCTX Gross profitLCTX Gross marginLCTX Operating incomeLCTX Operating marginLCTX Operating cash flowLCTX Free cash flowLCTX Capital expendituresLCTX Return on equityLCTX Stock buybacksLCTX Dividends paidLCTX Total assetsLCTX Shareholders’ equityLCTX overview →